MX338551B - Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. - Google Patents
Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.Info
- Publication number
- MX338551B MX338551B MX2013005833A MX2013005833A MX338551B MX 338551 B MX338551 B MX 338551B MX 2013005833 A MX2013005833 A MX 2013005833A MX 2013005833 A MX2013005833 A MX 2013005833A MX 338551 B MX338551 B MX 338551B
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- casein kinase
- pyridine compounds
- fused pyridine
- novel fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Abstract
Se describen compuestos y sales de estos aceptables desde el punto de vista farmacéutico, en donde los compuestos tienen la estructura de la Fórmula I: (Ver Formula) y sales de estos aceptables desde el punto de vista farmacéutico, en donde X, Y, A, R4, n y R7 son como se definen en la memoria descriptiva. También se describen composiciones farmacéuticas, métodos de tratamiento, métodos de síntesis e intermediarios correspondientes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425213P | 2010-12-20 | 2010-12-20 | |
| PCT/IB2011/055489 WO2012085721A1 (en) | 2010-12-20 | 2011-12-06 | Novel fused pyridine compounds as casein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005833A MX2013005833A (es) | 2013-07-05 |
| MX338551B true MX338551B (es) | 2016-04-20 |
Family
ID=45446116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005833A MX338551B (es) | 2010-12-20 | 2011-12-06 | Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8536164B2 (es) |
| EP (2) | EP2654750B1 (es) |
| JP (2) | JP5684923B2 (es) |
| KR (1) | KR101590236B1 (es) |
| CN (1) | CN103260622B (es) |
| AR (1) | AR084412A1 (es) |
| AU (1) | AU2011346733C1 (es) |
| CA (1) | CA2819961C (es) |
| CY (2) | CY1118772T1 (es) |
| DK (2) | DK3181133T3 (es) |
| ES (2) | ES2623387T3 (es) |
| HK (1) | HK1188145A1 (es) |
| HR (2) | HRP20170484T1 (es) |
| HU (2) | HUE032405T2 (es) |
| IL (1) | IL226948A (es) |
| LT (2) | LT2654750T (es) |
| MX (1) | MX338551B (es) |
| PL (2) | PL3181133T3 (es) |
| PT (2) | PT2654750T (es) |
| RS (2) | RS59098B1 (es) |
| SG (1) | SG190802A1 (es) |
| SI (2) | SI2654750T1 (es) |
| WO (1) | WO2012085721A1 (es) |
| ZA (1) | ZA201303453B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2460065T3 (es) * | 2009-10-28 | 2014-05-13 | Pfizer Inc. | Derivados de imidazol como inhibidores de la caseína quinasa |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9475817B2 (en) * | 2012-12-21 | 2016-10-25 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
| WO2015163446A1 (ja) * | 2014-04-25 | 2015-10-29 | 協和発酵キリン株式会社 | イミダゾール化合物の製造方法 |
| JP2017222576A (ja) * | 2014-10-31 | 2017-12-21 | 石原産業株式会社 | 有害生物防除剤 |
| CN107365315A (zh) * | 2016-05-11 | 2017-11-21 | 国药集团国瑞药业有限公司 | 一种吡唑类化合物、其晶型及其制备方法 |
| US10973820B2 (en) * | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| WO2021190616A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Methods for inhibiting casein kinases |
| WO2021190615A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| CN111808102B (zh) * | 2020-08-03 | 2021-12-31 | 南通大学 | 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法 |
| CN116171280A (zh) * | 2020-09-17 | 2023-05-26 | 詹森药业有限公司 | 酪蛋白激酶1δ调节剂 |
| KR20230069169A (ko) * | 2020-09-17 | 2023-05-18 | 얀센 파마슈티카 엔.브이. | 카제인 키나제 1 델타 조절제 |
| WO2022127755A1 (en) * | 2020-12-15 | 2022-06-23 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| WO2023241552A1 (en) * | 2022-06-14 | 2023-12-21 | Gritscience Biopharmaceuticals Co., Ltd | Salt and/or crystal form for compounds as casein kinase inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151962A3 (en) | 1984-01-25 | 1985-10-02 | Beecham Group Plc | Pyrazolopyridine derivatives |
| BR9809147A (pt) * | 1997-05-22 | 2000-08-01 | Searle & Co | Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis |
| AR029423A1 (es) * | 1999-12-21 | 2003-06-25 | Sugen Inc | Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos |
| SI1906965T1 (sl) | 2005-06-22 | 2015-09-30 | Chemocentryx, Inc. | Azaindolne spojine in postopki uporabe |
| US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| EP2308866A1 (de) * | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| ES2460065T3 (es) * | 2009-10-28 | 2014-05-13 | Pfizer Inc. | Derivados de imidazol como inhibidores de la caseína quinasa |
-
2011
- 2011-12-06 EP EP11805210.9A patent/EP2654750B1/en active Active
- 2011-12-06 SG SG2013036934A patent/SG190802A1/en unknown
- 2011-12-06 KR KR1020137015822A patent/KR101590236B1/ko active IP Right Grant
- 2011-12-06 LT LTEP11805210.9T patent/LT2654750T/lt unknown
- 2011-12-06 MX MX2013005833A patent/MX338551B/es active IP Right Grant
- 2011-12-06 PT PT118052109T patent/PT2654750T/pt unknown
- 2011-12-06 PL PL17151228T patent/PL3181133T3/pl unknown
- 2011-12-06 LT LTEP17151228.8T patent/LT3181133T/lt unknown
- 2011-12-06 PL PL11805210T patent/PL2654750T3/pl unknown
- 2011-12-06 HU HUE11805210A patent/HUE032405T2/en unknown
- 2011-12-06 WO PCT/IB2011/055489 patent/WO2012085721A1/en active Application Filing
- 2011-12-06 SI SI201131141A patent/SI2654750T1/sl unknown
- 2011-12-06 JP JP2013545540A patent/JP5684923B2/ja active Active
- 2011-12-06 CN CN201180061257.2A patent/CN103260622B/zh active Active
- 2011-12-06 DK DK17151228.8T patent/DK3181133T3/da active
- 2011-12-06 CA CA2819961A patent/CA2819961C/en active Active
- 2011-12-06 HU HUE17151228A patent/HUE047089T2/hu unknown
- 2011-12-06 ES ES11805210.9T patent/ES2623387T3/es active Active
- 2011-12-06 RS RS20191036A patent/RS59098B1/sr unknown
- 2011-12-06 EP EP17151228.8A patent/EP3181133B1/en active Active
- 2011-12-06 ES ES17151228T patent/ES2744099T3/es active Active
- 2011-12-06 RS RS20170387A patent/RS55897B1/sr unknown
- 2011-12-06 SI SI201131784T patent/SI3181133T1/sl unknown
- 2011-12-06 DK DK11805210.9T patent/DK2654750T3/en active
- 2011-12-06 AU AU2011346733A patent/AU2011346733C1/en active Active
- 2011-12-06 PT PT17151228T patent/PT3181133T/pt unknown
- 2011-12-13 US US13/323,883 patent/US8536164B2/en active Active
- 2011-12-19 AR ARP110104787A patent/AR084412A1/es not_active Application Discontinuation
-
2013
- 2013-05-13 ZA ZA2013/03453A patent/ZA201303453B/en unknown
- 2013-06-13 IL IL226948A patent/IL226948A/en active IP Right Grant
-
2014
- 2014-02-14 HK HK14101403.3A patent/HK1188145A1/xx unknown
-
2015
- 2015-01-14 JP JP2015005142A patent/JP5876596B2/ja active Active
-
2017
- 2017-03-22 HR HRP20170484TT patent/HRP20170484T1/hr unknown
- 2017-03-27 CY CY20171100378T patent/CY1118772T1/el unknown
-
2019
- 2019-08-14 HR HRP20191469 patent/HRP20191469T1/hr unknown
- 2019-08-21 CY CY20191100892T patent/CY1122062T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013005833A (es) | Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. | |
| PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
| PH12015500376A1 (en) | Novel bicyclic pyridinones | |
| IN2012DN03182A (es) | ||
| UA108926C2 (ru) | LibreOffice? [2,3-D] +" +" !+ | |
| UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| WO2014045162A8 (en) | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS | |
| MY149731A (en) | Compounds | |
| MY172924A (en) | Neprilysin inhibitors | |
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| MX2012002876A (es) | Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico. | |
| PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| GB201209587D0 (en) | Therapeutic compounds | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| GB201101517D0 (en) | Receptor antagonists | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| WO2011125006A3 (en) | Sultam compounds | |
| MX356499B (es) | Derivados de heteroarilamida novedosos que tienen propiedades antiandrogénicas. | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors | |
| MX2011012329A (es) | Nuevas sales farmaceuticamente aceptables de 4-(1h-imidazol-4-ilme til)piridina y sus usos terapeuticos. | |
| MX2015006806A (es) | Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |